Ironwood Pharmaceuticals (NASDAQ:IRWD – Get Free Report) was upgraded by research analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating in a research report issued to clients and investors on Saturday, Wall Street Zen reports.
IRWD has been the subject of several other research reports. Jefferies Financial Group upgraded Ironwood Pharmaceuticals to a “hold” rating in a report on Friday, September 25th. Zacks Research downgraded Ironwood Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 30th. Finally, Weiss Ratings raised Ironwood Pharmaceuticals from a “hold (c)” rating to a “hold (c+)” rating in a research report on Thursday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $6.23.
Check Out Our Latest Stock Analysis on IRWD
Ironwood Pharmaceuticals Stock Performance
IRWD stock opened at $4.39 on Friday. The firm has a market cap of $725.40 million, a price-to-earnings ratio of 4.88 and a beta of 0.25. The firm has a 50-day simple moving average of $3.91 and a two-hundred day simple moving average of $3.97. Ironwood Pharmaceuticals has a one year low of $1.88 and a one year high of $5.78.
Ironwood Pharmaceuticals (NASDAQ:IRWD – Get Free Report) last announced its earnings results on Thursday, November 5th. The biotechnology company reported $0.36 earnings per share for the quarter, beating the consensus estimate of $0.32 by $0.04. Ironwood Pharmaceuticals had a net margin of 37.38% and a negative return on equity of 81.40%. The company had revenue of $133.04 million during the quarter, compared to the consensus estimate of $119.99 million. As a group, equities analysts predict that Ironwood Pharmaceuticals will post 1.10 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Ironwood Pharmaceuticals
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Principal Financial Group Inc. acquired a new position in Ironwood Pharmaceuticals in the first quarter valued at approximately $40,000. Y Intercept Hong Kong Ltd purchased a new stake in Ironwood Pharmaceuticals in the 1st quarter worth approximately $47,000. Bull Harbor Capital LLC purchased a new stake in Ironwood Pharmaceuticals in the 1st quarter worth approximately $48,000. Ascent Group LLC acquired a new stake in shares of Ironwood Pharmaceuticals during the 3rd quarter worth approximately $58,000. Finally, DGS Capital Management LLC grew its stake in shares of Ironwood Pharmaceuticals by 42.8% during the 1st quarter. DGS Capital Management LLC now owns 14,883 shares of the biotechnology company’s stock worth $52,000 after purchasing an additional 4,458 shares during the period.
Trending Headlines about Ironwood Pharmaceuticals
Here are the key news stories impacting Ironwood Pharmaceuticals this week:
- Positive Sentiment: Ironwood reported Q3 adjusted earnings of $0.36 per share, above analyst expectations, while net income rose 49% year over year. It raised 2026 revenue guidance to $485 million–$510 million, above the roughly $470.5 million consensus, and increased its EBITDA outlook. Management also cited stronger Linzess sales expectations and profitability. Ironwood Q3 net income rises and outlook increases
- Neutral Sentiment: Revenue commentary was inconsistent: one Zacks headline described revenue as missing expectations, while reported figures of $133.04 million exceeded the estimate of $119.99 million cited elsewhere. Zacks Q3 earnings and outlook coverage
About Ironwood Pharmaceuticals
Ironwood Pharmaceuticals, Inc is a gastrointestinal-focused biopharmaceutical company headquartered in Boston, Massachusetts. The company discovers, develops, and commercializes medicines intended to treat disorders affecting the gastrointestinal tract, with an emphasis on conditions involving gut motility and visceral sensitivity.
Ironwood’s principal commercial product is Linzess (linaclotide), marketed in the United States in collaboration with AbbVie. Linzess is approved for adults with irritable bowel syndrome with constipation and chronic idiopathic constipation.
Recommended Stories
- Five stocks we like better than Ironwood Pharmaceuticals
- Lemonade’s Revenue Soars 73%—So Why Did Its Stock Turn Sour After Earnings?
- Anthropic’s S-1 Strengthens the Case for Broadcom’s AI Growth
- After the Midterms, Which of These 3 Defense ETFs Looks Strongest?
- The Ugly Truth Behind SoundHound’s Q3 Results
Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
